Location: Doylestown,PA, USA
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company's pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com.
Imvotamab in Autoimmune and Inflammatory Diseases
Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).
Position Summary
We seek a Scientist / Senior Scientist willing to do bench work and be a strategic thinker. The ideal candidate has deep knowledge of adaptive and innate immunity in inflammatory and autoimmune diseases, focusing on B and T cells. The selected candidate will based in either the San Francisco Bay Area or Doylestown, PA, will have experience with T-cell engagers or CAR-Ts, and will be an expert in multi-parameter flow cytometry of primary human and mouse cells with a broad understanding and practical application of cell-based assays to address the function of T-cell engager antibodies. A significant advantage is having experience in clinical biomarker strategy design and execution through CROs and internal resources.
As a Scientist in clinical Biomarkers, Autoimmune, and inflammation, you will assist with driving biomarker and drug development efforts for our clinical programs in autoimmunity. The optimal candidate will have a strong scientific background, curiosity and creativity, experience leading and executing autoimmunity or immunology-focused programs, a strong drive to succeed, and the ability to work well with other research, translational, and clinical scientists.
Responsibilities:
For all level Scientists: